子宫切除术时阴道抗菌准备:系统综述与荟萃分析
本系统综述与荟萃分析检索1985年1月1日至2023年12月7日数据库,纳入10项研究共9618例受试者,比较子宫切除术前阴道氯己定与聚维酮碘消毒。荟萃分析显示手术部位感染无统计学显著差异(汇总OR 1.22,95%CI 0.91-1.63),氯己定组阴道培养阳性率更低(汇总OR 0.10,95%CI 0.04-0.27)。
要点
- 氯己定与聚维酮碘阴道准备后手术部位感染无统计学显著差异(汇总OR 1.22,95%CI 0.91-1.63)。
- 氯己定组术中阴道培养阳性率更低(汇总OR 0.10,95%CI 0.04-0.27)。
- 氯己定不良反应报告不足,但风险似乎较低;2例病例报告描述阴道脱屑或超敏反应。
核心结论
- 氯己定与聚维酮碘相比术后感染无差异证据,但氯己定阴道准备可降低术中阴道培养阳性率。
- 尽管报告不充分,不良事件风险似乎较低。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和ClinicalTrials.gov数据库,时间自1985年1月1日至2023年12月7日。
- 纳入随机对照试验和非随机比较研究,比较氯己定与聚维酮碘阴道抗菌准备。
- 共筛选5289篇摘要,10项研究符合纳入标准,共9618例受试者。
- 纳入研究包括4项随机对照试验(n=306)、3项前瞻性非随机比较(n=1089)和3项回顾性非随机比较(n=8223)。
主要发现
- 聚维酮碘与4%氯己定比较4项研究(n=2491),与2%氯己定比较2项研究(n=236),与0.1%氯己定比较1项研究(n=50),与2%和4%氯己定比较1项研究(n=49)。
- 手术部位感染荟萃分析无统计学显著差异,但氯己定组略常见(汇总OR 1.22,95%CI 0.91-1.63)。
- 尿路感染相对效应不明确,汇总OR不精确(1.18,95%CI 0.65-2.12)。
- 氯己定准备组阴道培养阳性更少见(汇总OR 0.10,95%CI 0.04-0.27)。
- 2项研究报告氯己定无不良事件,2项发现与聚维酮碘相比阴道刺激无差异;2例病例报告描述氯己定相关阴道脱屑或超敏反应。
关键数值与推荐
- 主要结局为疾病控制与预防中心定义的手术部位感染。
- 次要结局包括术后尿路感染和阴道培养标本。
- 方法学质量使用原始Cochrane RoB和ROBINS-I工具评估,采用限制最大似然法进行OR荟萃分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 尽管报告不充分,不良事件风险似乎较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to compare the rates of surgical site infection after hysterectomy using vaginal antisepsis with chlorhexidine gluconate vs povidone-iodine. DATA SOURCES: PubMed, Embase, and ClinicalTrials.gov databases were queried from January 1, 1985 through December 7, 2023. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials and nonrandomized comparisons of interventions of chlorhexidine gluconate and povidone-iodine vaginal antiseptic preparation before hysterectomy were included. The primary outcome was surgical site infection as defined by the Centers for Disease Control and Prevention. Secondary outcomes included postoperative urinary tract infections and vaginal culture specimens. Large single-group studies of vaginal chlorhexidine gluconate reporting adverse events and case reports of desquamation were also included. METHODS: The methodologic quality of each study was assessed using the original Cochrane RoB (Risk of Bias) and ROBINS-I (Risk of Bias in Non-Randomized Studies - of Interventions) tools. Restricted maximum likelihood meta-analyses of odds ratios were conducted. RESULTS: A total of 5289 abstracts were screened; 10 met the inclusion criteria, with a total of 9618 participants. The studies included 4 randomized controlled trials (n=306), 3 prospective nonrandomized comparisons of interventions (n=1089), and 3 retrospective nonrandomized comparisons of interventions (n=8223). Povidone-iodine was compared with 4% chlorhexidine gluconate in 4 studies (n=2491), 2% chlorhexidine gluconate in 2 studies (n=236), 0.1% chlorhexidine gluconate in 1 study (n=50), and both 2% and 4% chlorhexidine gluconate in 1 study (n=49). Meta-analysis revealed no statistically significant difference in surgical site infections, although they were somewhat more common with chlorhexidine gluconate (summary odds ratio, 1.22; 95% confidence interval, 0.91-1.63). The relative effect of antiseptic preparations on urinary tract infections was unclear, with an imprecise summary odds ratio (1.18; 95% confidence interval, 0.65-2.12). Positive vaginal cultures were less common with chlorhexidine gluconate preparation (summary odds ratio, 0.10; 95% confidence interval, 0.04-0.27). Two studies reported no adverse events with chlorhexidine gluconate, and 2 found no difference in vaginal irritation when compared with povidone-iodine. Two case reports described vaginal desquamation or hypersensitivity with chlorhexidine gluconate. CONCLUSION: There is no evidence of a difference in postoperative infection with chlorhexidine gluconate use compared with povidone-iodine, but chlorhexidine gluconate vaginal preparation results in lower rates of positive intraoperative vaginal cultures. Despite inadequate reporting, risk of adverse events appears low.
引用
- Rozycki SK, Nguyen V, Miroballi N, et al. Vaginal antiseptic preparation at the time of hysterectomy: a systematic review and meta-analysis. Am J Obstet Gynecol. 2025. PMID: 39788360. doi:10.1016/j.ajog.2024.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。